Differential Physiological and Behavioral Cues Observed in Individuals Smoking Botanical Marijuana versus Synthetic Cannabinoid Drugs
Peter B. Chasea, Jeff Hawkinsb, Jarred Mosierc, Ernest Jimenezd, Keith Boesena, Barry K. Logane & Frank G. Waltera,c
aArizona Poison and Drug Information Center, The University of Arizona College of Pharmacy, Tucson, AZ, USA; bTucson Police Department, Tucson, AZ, USA; cDepartment of Emergency Medicine, The University of Arizona College of Medicine, Tucson, AZ, USA; dLCMS Laboratories, Tucson, AZ, USA; eNMS Labs, Willow Grove, PA, USA
The article Differential Physiological and Behavioral Cues Observed in Individuals Smoking Botanical Marijuana versus Synthetic Cannabinoid Drugs appears in Clinical Toxicology, 54:1, 14-19, DOl: 10.3109/15563650.2015.1101769. Abstract is included below.
Please e-mail us if you would like a PDF copy of the published article.
ABSTRACT: Synthetic cannabinoid use has increased in many states, and medicinal and/or recreational marijuana use has been legalized in some states. These changes present challenges to law enforcement drug recognition experts (DREs) who determine whether drivers are impaired by synthetic cannabinoids or marijuana, as well as to clinical toxicologists who care for patients with complications from synthetic cannabinoids and marijuana. Our goal was to compare what effects synthetic cannabinoids and marijuana had on performance and behavior, including driving impairment, by reviewing records generated by law enforcement DREs who evaluated motorists arrested for impaired driving. Methods: Data were from a retrospective, convenience sample of de-identified arrest reports from impaired drivers suspected of using synthetic cannabinoids (n = 100) or marijuana (n = 33). Inclusion criteria were arrested drivers who admitted to using either synthetic cannabinoids or marijuana, or who possessed either synthetic cannabinoids or marijuana; who also had a DRE evaluation at the scene; and whose blood screens were negative for alcohol and other drugs. Exclusion criteria were impaired drivers arrested with other intoxicants found in their drug or alcohol blood screens. Blood samples were analyzed for 20 popular synthetic cannabinoids by using liquid chromatography-tandem mass spectrometry. Delta-9-tetrahydrocannabinol (THC) and THC-COOH were quantified by gas chromatography-mass spectrometry. Statistical significance was determined by using Fisher's exact test or Student's t-test, where appropriate, to compare the frequency of characteristics of those in the synthetic cannabinoid group versus those in the marijuana group. Results: 16 synthetic cannabinoid and 25 marijuana records met selection criteria; the drivers of these records were arrested for moving violations. Median age for the synthetic cannabinoid group (n = 16, 15 males) was 20 years (IQR 19-23 years). Median age for the marijuana group (n = 25, 21 males) was 20 years (IQR 19-24 years) (p = 0.46). In the synthetic cannabinoid group, 94% (15/16) admitted to using synthetic cannabinoids. In the marijuana group, 96% (24/25) admitted to using marijuana. Blood was available for testing in 96% (24/25) of the marijuana group; 21 of these 24 had quantitative levels of THC (mean+ SD = 10.7 + 5 ng/mL) and THC-COOH (mean+ SD = 57.8 + 3 ng/mL). Blood was available for testing in 63% (10/16) of the synthetic cannabinoid group, with 80% (8/10) of these positive for synthetic cannabinoids. Those in the synthetic cannabinoid group were more frequently confused (7/16 [44%] vs. 0/25 [0%], p <:: 0.003) and disoriented (5/16 [31%] vs. 0/25 [0%], p <:: 0.003), and more frequently had incoherent, slurred speech (10/16 [63%] vs. 3/25 [12%], p = 0.0014) and horizontal gaze nystagmus (8/16 [50%] vs. 3/25 [12%], p = 0.01) than those in the marijuana group. Conclusion: Drivers under the influence of synthetic cannabinoids were more frequently impaired with confusion, disorientation, and incoherent, slurred speech than drivers under the influence of marijuana in this population evaluated by DREs.
NMS Labs is the only independent forensic facility in the nation to be certified by both the ABFT (American Board of Forensic Toxicology) and ANAB-ASCLD/LAB-International (ANSI/ASQ National Accreditation Board-American Society of Crime Lab Directors/Lab Accreditation Board ISO 17025). ISO 17025 accreditation covers the disciplines of Toxicology, DNA, serology and controlled substances. We diligently maintain and exceed the high standards set by these organizations, so that you can have the utmost confidence in your testing results.